IKT Inhibikase Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1750149 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-45.1%
TTM EPS YoY-185.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-52.9%
ROA-49.2%
ROIC (approx.)-68.9%
Asset turnover—
Leverage & solvency
Liabilities / assets6.4%
Debt / equity0.00x
Current ratio15.34x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-14.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | $0 |
| R&D expense | $29.79M | $17.21M |
| SG&A expense | $23.56M | $11.38M |
| Operating income | -$51.97M | -$28.59M |
| Pretax income | -$48,259 | -$27,520 |
| Income tax | $0 | $0 |
| Net income | -$48.26M | -$27.52M |
| EBITDA | -$51.91M | -$28.56M |
| EPS (basic) | -0.49 | -1.16 |
| EPS (diluted) | -0.49 | -1.16 |
| Weighted avg. shares (diluted) | 98.31M | 23.71M |
| Banking | ||
| Net interest income | $3.72M | $1.07M |
| Balance sheet | ||
| Cash & equivalents | $139.22M | $56.49M |
| Short-term investments | $39.54M | $41.05M |
| Current assets | $180.11M | $98.45M |
| PP&E, net | $0 | $47,100 |
| Total assets | $181.20M | $98.60M |
| Current liabilities | $8.30M | $3.73M |
| Short-term debt | $0 | $110,517 |
| Total liabilities | $8.30M | $3.73M |
| Shareholders' equity | $172.90M | $94.87M |
| Shares outstanding | 131.69M | 69.36M |
| Cash flow statement | ||
| Operating cash flow | -$27.79M | -$19.15M |
| Capital expenditure | $13,399 | $0 |
| Free cash flow | -$27.80M | -$19.15M |
| Investing cash flow | $2.05M | -$37.00M |
| Financing cash flow | $108.46M | $103.48M |
| Depreciation & amortization | $60,499 | $26,272 |
| Stock-based compensation | $15.31M | $8.14M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.